Kevan R Polkinghorne

List of Publications by Year
in descending order

209 papers	9,989 citations	46984 47 h-index	42364 92 g-index
211 all docs	211 docs citations	211 times ranked	11894 citing authors

#	Article	IF	Citations
1	Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate. JAMA - Journal of the American Medical Association, 2012, 307, 1941-51.	3.8	810
2	Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. New England Journal of Medicine, 2013, 369, 932-943.	13.9	729
3	Vascular Access and All-Cause Mortality: A Propensity Score Analysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 477-486.	3.0	384
4	Relationship between Dialysis Modality and Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 155-163.	3.0	282
5	Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney International, 2019, 95, 160-172.	2.6	277
6	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	2.6	235
7	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. American Journal of Kidney Diseases, 2016, 68, 444-454.	2.1	232
8	Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. American Journal of Kidney Diseases, 2010, 55, 660-670.	2.1	231
9	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. American Journal of Kidney Diseases, 2017, 70, 464-475.	2.1	218
10	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 586-593.	0.4	214
11	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
12	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	3.0	194
13	Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Medical Journal of Australia, 2012, 197, 224-225.	0.8	179
14	Diagnostic Accuracy of Urine Dipsticks for Detection of Albuminuria in the General Community. American Journal of Kidney Diseases, 2011, 58, 19-28.	2.1	170
15	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases, 2011, 58, 782-793.	2.1	168
16	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrologyâ€“Hemodialysis (SONG-HD) Consensus Workshop. American Journal of Kidney Diseases, 2017, 69, 97-107.	2.1	148
17	Conversion of Urine Proteinâ€“Creatinine Ratio or Urine Dipstick Protein to Urine Albuminâ€“Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. Annals of Internal Medicine, 2020, 173, 426-435.	2.0	144
18	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	2.6	126

#	Article	IF	Citations
19	Alcohol consumption and 5-year onset of chronic kidney disease: the AusDiab study. Nephrology Dialysis Transplantation, 2009, 24, 2464-2472.	0.4	123
20	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Medical Journal of Australia, 2012, 197, 222-223.	0.8	112
21	Time and exercise improve phosphate removal in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 85-89.	2.1	110
22	Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases, 2011, 58, 64-72.	2.1	110
23	Attenuation of aortic calcification with lanthanum carbonate versus calciumâ€based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology, 2011, 16, 290-298.	0.7	109
24	Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. American Journal of Kidney Diseases, 2010, 56, 57-68.	2.1	99
25	<scp>KHAâ€CARI</scp> Guideline: Vascular access â€“ central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology, 2013, 18, 701-705.	0.7	93
26	Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 110-119.	2.2	93
27	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. American Journal of Kidney Diseases, 2018, 72, 188-197.	2.1	85
28	Optimal Hemodialysis Vascular Access in the Elderly Patient. Seminars in Dialysis, 2012, 25, 640-648.	0.7	84
29	Histopathologic and Clinical Predictors of Kidney Outcomes inÂANCA-Associated Vasculitis. American Journal of Kidney Diseases, 2014, 63, 227-235.	2.1	80
30	Impact of intradialytic exercise on arterial compliance and Bâ€type natriuretic peptide levels in hemodialysis patients. Hemodialysis International, 2008, 12, 254-263.	0.4	79
31	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	2.6	77
32	Barriers to Timely Arteriovenous Fistula Creation: A Study of Providers and Patients. American Journal of Kidney Diseases, 2011, 57, 873-882.	2.1	76
33	Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosisâ€”a randomized controlled trial. Nephrology Dialysis Transplantation, 2006, 21, 2498-2506.	0.4	74
34	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.	2.1	73
35	Effect of a Vascular Access Nurse Coordinator to Reduce Central Venous Catheter Use in Incident Hemodialysis Patients: A Quality Improvement Report. American Journal of Kidney Diseases, 2009, 53, 99-106.	2.1	71
36	Identification of alternatively activated macrophages in newâ€onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology, 2011, 58, 198-210.	1.6	68

#	Article	IF	Citations
37	Standardised outcomes in nephrology â€“ Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials, 2015, 16, 364.	0.7	67
38	Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. American Journal of Kidney Diseases, 2007, 49, 301-309.	2.1	62
39	Report of the Standardized Outcomes in Nephrologyâ€“Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure forÂHemodialysis Vascular Access. American Journal of Kidney Diseases, 2018, 71, 690-700.	2.1	62
40	Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney International, 2012, 82, 212-219.	2.6	60
41	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology, 2009, 10, 1.	0.8	58
42	Risk factors for peritoneal dialysis-related peritonitis: Can we reduce the incidence and improve patient selection?. Nephrology, 2007, 12, 239-245.	0.7	53
43	Limited knowledge of kidney disease in a survey of AusDiab study participants. Medical Journal of Australia, 2008, 188, 204-208.	0.8	53
44	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	3.0	52
45	The association between patient activation and selfâ€care practices: A crossâ€sectional study of an Australian population with comorbid diabetes and chronic kidney disease. Health Expectations, 2017, 20, 1375-1384.	1.1	51
46	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) Tj ETQq0 0 0 rgBT /Overlock 10 T Nephrology: CJASN, 2015, 10, 1397-1407.	2.2	50
47	Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine, 2020, 27, 100552.	3.2	50
48	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	2.1	49
49	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. American Journal of Kidney Diseases, 2013, 61, 96-103.	2.1	48
50	Longitudinal Body Composition Changes Due to Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1668-1675.	2.2	47
51	The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. Kidney International, 2017, 92, 1469-1475.	2.6	47
52	Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and Thailand. American Journal of Public Health, 2008, 98, 1306-1313.	1.5	45
53	Serum 25-Hydroxyvitamin D Deficiency and the 5-Year Incidence of CKD. American Journal of Kidney Diseases, 2013, 62, 58-66.	2.1	45
54	The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled. Seminars in Dialysis, 2018, 31, 244-257.	0.7	45

#	Article	IF	Citations
55	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney International, 2016, 89, 1337-1345.	2.6	44
56	Quantifying the excess risk for proteinuria, hypertension and diabetes in Australian Aborigines: comparison of profiles in three remote communities in the Northern Territory with those in the AusDiab study. Australian and New Zealand Journal of Public Health, 2007, 31, 177-183.	0.8	43
57	JNK signalling in human and experimental renal ischaemia/reperfusion injury. Nephrology Dialysis Transplantation, 2010, 25, 2898-2908.	0.4	42
58	Intensive Hemodialysis and Mortality Risk in Australian andÂNewÂZealand Populations. American Journal of Kidney Diseases, 2016, 67, 617-628.	2.1	42
59	Survival on Home Dialysis in New Zealand. PLoS ONE, 2014, 9, e96847.	1.1	41
60	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases, 2015, 66, 489-498.	2.1	41
61	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. American Journal of Kidney Diseases, 2018, 71, 382-391.	2.1	41
62	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. PLoS ONE, 2016, 11, e0146615.	1.1	40
63	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrology Dialysis Transplantation, 2011, 26, 1319-1326.	0.4	39
64	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 2018, 72, 62-74.	2.1	39
65	Population Prevalence of Albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study: Immunonephelometry Compared With High-Performance Liquid Chromatography. American Journal of Kidney Diseases, 2006, 47, 604-613.	2.1	38
66	Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 119-127.	2.2	38
67	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. BMJ Open, 2017, 7, e017695.	0.8	38
68	Physical inactivity and chronic kidney disease in Australian adults: The AusDiab study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 104-112.	1.1	37
69	Waterâ€soluble vitamin levels in extended hours hemodialysis. Hemodialysis International, 2011, 15, 30-38.	0.4	37
70	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	1.1	37
71	Elderly patients with CKDâ€"dilemmas in dialysis therapy and vascular access. Nature Reviews Nephrology, 2014, 10, 116-122.	4.1	37
72	Anthropometric measurements of Australian Aboriginal adults living in remote areas: Comparison with nationally representative findings. American Journal of Human Biology, 2008, 20, 317-324.	0.8	35

#	Article	IF	Citations
73	Relationship between vascular calcification, arterial stiffness and bone mineral density in a crossâ€sectional study of prevalent Australian haemodialysis patients. Nephrology, 2009, 14, 105-112.	0.7	35
74	Fatal Dialysis Vascular Access Hemorrhage. American Journal of Kidney Diseases, 2017, 70, 570-575.	2.1	35
75	Vascular access surveillance. Nephrology, 2008, 13, S1-11.	0.7	33
76	25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	33
77	Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. American Journal of Kidney Diseases, 2019, 73, 300-308.	2.1	33
78	Detection and measurement of urinary protein. Current Opinion in Nephrology and Hypertension, 2006, 15, 625-630.	1.0	32
79	Trends in Hemodialysis Vascular Access From the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) 2000 to 2005. American Journal of Kidney Diseases, 2007, 50, 612-621.	2.1	29
80	Predictors and Outcomes of Transfers from Peritoneal Dialysis to Hemodialysis. Peritoneal Dialysis International, 2015, 35, 306-315.	1.1	29
81	Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics. Kidney International Reports, 2021, 6, 272-283.	0.4	28
82	Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race. JAMA - Journal of the American Medical Association, 2022, 327, 2306.	3.8	28
83	Native arteriovenous fistula blood flow and resistance during hemodialysis. American Journal of Kidney Diseases, 2003, 41, 132-139.	2.1	27
84	Epidemiology of vascular access in the Australian hemodialysis population. Kidney International, 2003, 64, 1893-1902.	2.6	27
85	ADHERENCE TO GUIDELINES FOR PREVENTION OF POSTSPLENECTOMY SEPSIS. AGE AND SEX ARE RISK FACTORS: A FIVE-YEAR RETROSPECTIVE REVIEW. ANZ Journal of Surgery, 2006, 76, 542-547.	0.3	27
86	HPLC-Detected Albuminuria Predicts Mortality. Journal of the American Society of Nephrology: JASN, 2007, 18, 3171-3176.	3.0	27
87	Reduction in Î²2-Microglobulin With Super-flux Versus High-flux Dialysis Membranes: Results of a 6-Week, Randomized, Double-blind, Crossover Trial. American Journal of Kidney Diseases, 2008, 52, 93-101.	2.1	27
88	The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Quality of Life Research, 2019, 28, 2081-2090.	1.5	27
89	Patient survival on haemodiafiltration and haemodialysis: a cohort study using the Australia and New Zealand Dialysis and Transplant Registry. Nephrology Dialysis Transplantation, 2019, 34, 326-338.	0.4	26
90	Lateral lumbar Xâ€ray assessment of abdominal aortic calcification in Australian haemodialysis patients. Nephrology, 2011, 16, 389-395.	0.7	25

#	Article	IF	Citations
91	Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone, 2016, 85, 55-58.	1.4	25
92	Leukocyte phenotype and function predicts infection risk in renal transplant recipients. Nephrology Dialysis Transplantation, 2005, 20, 2226-2230.	0.4	24
93	Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. Diabetes Research and Clinical Practice, 2014, 104, 84-91.	1.1	24
94	Vascular access practice patterns in the New Zealand hemodialysis population. American Journal of Kidney Diseases, 2004, 43, 696-704.	2.1	23
95	Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis. Medical Journal of Australia, 2006, 185, 310-314.	0.8	23
96	High rates of albuminuria but not of low eGFR in Urban Indigenous Australians: the DRUID Study. BMC Public Health, 2011, 11, 346.	1.2	22
97	Early pancreas allograft thrombosis. Clinical Transplantation, 2013, 27, 410-416.	0.8	22
98	Seroresponses and safety of 13â€valent pneumococcal conjugate vaccination in kidney transplant recipients. Transplant Infectious Disease, 2018, 20, e12866.	0.7	22
99	Type 2 diabetes in patients with endâ€stage kidney disease: influence on cardiovascular diseaseâ€related mortality risk. Medical Journal of Australia, 2018, 209, 440-446.	0.8	22
100	Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 657-668.	0.4	22
101	Home hemodialysis in Australia: Current perspective. Hemodialysis International, 2008, 12, S6-S10.	0.4	21
102	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology, 2015, 16, 89.	0.8	21
103	Are traditional risk factors valid for assessing cardiovascular risk in endâ€stage renal failure patients?. Nephrology, 2008, 13, 667-671.	0.7	20
104	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. Nephrology Dialysis Transplantation, 2015, 30, 1897-1904.	0.4	20
105	Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease. Nephrology Dialysis Transplantation, 2017, 32, gfw383.	0.4	20
106	Natural killer cell function predicts severe infection in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 166-177.	2.6	20
107	Comparison of biochemical, haematological and volume parameters in two treatment schedules of nocturnal home haemodialysis. Nephrology, 2006, 11, 413-418.	0.7	19
108	Intraâ€dialytic hypotension and blood volume and blood temperature monitoring. Nephrology, 2011, 16, 13-18.	0.7	19

#	Article	IF	Citations
109	Water quality in conventional and home haemodialysis. Nature Reviews Nephrology, 2012, 8, 725-734.	4.1	19
110	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney International, 2021, 99, 466-474.	2.6	18
111	Predictive Value of Nephelometric and High-Performance Liquid Chromatography Assays of Urine Albumin for Mortality in a High-Risk Aboriginal Population. American Journal of Kidney Diseases, 2008, 52, 672-682.	2.1	17
112	Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology, 2011, 16, 261-268.	0.7	17
113	Primary and tertiary health professionalsâ€™ views on the health-care of patients with co-morbid diabetes and chronic kidney disease â€“ a qualitative study. BMC Nephrology, 2016, 17, 50.	0.8	17
114	Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study. Journal of Alzheimer's Disease, 2019, 70, S19-S30.	1.2	17
115	Controversies in chronic kidney disease staging. Clinical Biochemist Reviews, 2011, 32, 55-9.	3.3	17
116	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. Peritoneal Dialysis International, 2016, 36, 547-554.	1.1	16
117	Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Hemodialysis International, 2007, 11, 217-224.	0.4	15
118	Dialysis modality, vascular access and mortality in endâ€stage kidney disease: A biâ€national registryâ€based cohort study. Nephrology, 2016, 21, 878-886.	0.7	15
119	Early serum creatinine accurately predicts acute kidney injury post cardiac surgery. BMC Nephrology, 2017, 18, 93.	0.8	15
120	Epidemiology and Outcomes of Acute Kidney Diseases: A Comparative Analysis. American Journal of Nephrology, 2021, 52, 342-350.	1.4	15
121	Determinants of native arteriovenous fistula blood flow. Nephrology, 2004, 9, 205-211.	0.7	14
122	Measurement of vascular calcification using CT fistulograms. Nephrology Dialysis Transplantation, 2006, 22, 484-490.	0.4	14
123	Cystatin C estimated glomerular filtration rate and allâ€cause and cardiovascular disease mortality risk in the general population: AusDiab study. Nephrology, 2017, 22, 243-250.	0.7	14
124	Models of care for coâ€morbid diabetes and chronic kidney disease. Nephrology, 2018, 23, 711-717.	0.7	14
125	Endothelial Progenitor Cells and Vascular Health inÂDialysis Patients. Kidney International Reports, 2018, 3, 205-211.	0.4	14
126	Effect of exercise on albuminuria in people with diabetes. Nephrology, 2011, 16, 704-709.	0.7	13

#	Article	IF	Citations
127	Omega-3 Polyunsaturated Fatty Acid Supplementation toÂPrevent Arteriovenous Fistula and Graft Failure: AÂSystematic Review and Meta-analysis of RandomizedÂControlled Trials. American Journal of Kidney Diseases, 2018, 72, 50-61.	2.1	13
128	Risk factors for major adverse kidney events in the first year after acute kidney injury. CKJ: Clinical Kidney Journal, 2021, 14, 556-563.	1.4	13
129	Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease. Nephrology, 2010, 15, 575-583.	0.7	12
130	Clustering and Residual Confounding in the Application of Marginal Structural Models: Dialysis Modality, Vascular Access, and Mortality. American Journal of Epidemiology, 2015, 182, 535-543.	1.6	12
131	Prevalence of chronic kidney disease in the elderly using the ASPirin in Reducing Events in the Elderly study cohort. Nephrology, 2019, 24, 1248-1256.	0.7	12
132	Blood Pressure and Blood Volume: Acute and Chronic Considerations in Hemodialysis. Seminars in Dialysis, 2013, 26, 62-72.	0.7	11
133	Longâ€term graft survival in patients with chronic antibodyâ€mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. Clinical Transplantation, 2017, 31, e13037.	0.8	11
134	The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort. BMC Nephrology, 2018, 19, 325.	0.8	11
135	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. PLoS ONE, 2019, 14, e0219685.	1.1	11
136	Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Research and Care, 2020, 8, e000842.	1.2	11
137	Patient-led identification and prioritization of exercise interventions for fatigue on dialysis: a workshop report. CKJ: Clinical Kidney Journal, 2021, 14, 831-839.	1.4	11
138	Global Dialysis Perspective: Australia. Kidney360, 2020, 1, 48-51.	0.9	11
139	Vascular Access Practice in Hemodialysis: Instrumental in Determining Patient Mortality. American Journal of Kidney Diseases, 2009, 53, 359-362.	2.1	10
140	Baseline characteristics of the omegaâ€3 fatty acids (<scp>F</scp>ish oils) and <scp>A</scp>spirin in <scp>V</scp>ascular access <scp>OU</scp>tcomes in <scp>RE</scp>nal <scp>D</scp>isease (<scp>FAVOURED</scp>) study. Nephrology, 2016, 21, 217-228.	0.7	10
141	Total volume and composition of fluid intake and mortality in older women: a cohort study. BMJ Open, 2017, 7, e011720.	0.8	10
142	Changes in Body Mass Index and Rates of Death and Transplant in Hemodialysis Patients. Epidemiology, 2019, 30, 38-47.	1.2	10
143	Home Versus Facility Dialysis and Mortality in Australia and New Zealand. American Journal of Kidney Diseases, 2021, 78, 826-836.e1.	2.1	10
144	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	1.2	9

#	Article	IF	Citations
145	Dialysis catheter management practices in Australia and New Zealand. Nephrology, 2019, 24, 827-834.	0.7	9
146	Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. Scientific Reports, 2020, 10, 19379.	1.6	9
147	Long-Term Blood Pressure Variability and Kidney Function in Participants of the ASPREE Trial. American Journal of Hypertension, 2022, 35, 173-181.	1.0	9
148	Estimated Glomerular Filtration Rate versus Albuminuria in the Assessment of Kidney Function: What's More Important?. Clinical Biochemist Reviews, 2014, 35, 67-73.	3.3	9
149	Body composition in home haemodialysis versus conventional haemodialysis: a cross-sectional, matched, comparative study. Nephrology Dialysis Transplantation, 2010, 25, 568-573.	0.4	8
150	Vascular Access Surveillance: Time to End the Controversy. Seminars in Dialysis, 2013, 26, 257-259.	0.7	8
151	Different faces of <scp>N</scp>ocardia infection in renal transplant recipients. Nephrology, 2016, 21, 254-260.	0.7	8
152	Longâ€term outcomes of endâ€stage kidney disease for patients with <scp>IgA</scp> nephropathy: A multiâ€centre registry study. Nephrology, 2016, 21, 387-396.	0.7	8
153	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE, 2019, 14, e0213274.	1.1	8
154	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. Kidney360, 2020, 1, 1259-1269.	0.9	8
155	REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) â€“ design and baseline results. Kidney360, 2020, 1, 746-754.	0.9	8
156	Pharmacological approaches to preventing vascular access failure. Nephrology, 2008, 13, S12-6.	0.7	7
157	<scp>DEBATE</scp>: Should Dialysis at Home be Mandatory for All Suitable <scp>ESRD</scp> Patients?. Seminars in Dialysis, 2015, 28, 147-154.	0.7	7
158	Survival in Living Kidney Donors: An Australian and New Zealand Cohort Study Using Data Linkage. Transplantation Direct, 2020, 6, e533.	0.8	7
159	Vancomycin-resistant enterococci colonization does not increase mortality in end-stage kidney failure: a caseâ€“control study. Journal of Hospital Infection, 2013, 85, 289-296.	1.4	6
160	Can We Predict the Unpredictable after Vascular Access Creation?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1729-1731.	2.2	6
161	Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial. Hemodialysis International, 2017, 21, 19-28.	0.4	6
162	A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2Âyears. Transplant Infectious Disease, 2019, 21, e13076.	0.7	6

#	Article	IF	Citations
163	The impact of comorbid chronic kidney disease and diabetes on health-related quality-of-life: aÂ12-year community cohort study. Nephrology Dialysis Transplantation, 2021, 36, 1048-1056.	0.4	6
164	Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial. BMJ, The, 2022, 377, e069634.	3.0	6
165	Arteriovenous Fistula Patency: Some Answers but Questions Remain. American Journal of Kidney Diseases, 2014, 63, 384-386.	2.1	5
166	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 215.	1.0	5
167	ESKD or Cancer: Given the Choice, Which Would You Rather Have?. American Journal of Kidney Diseases, 2019, 73, 753-755.	2.1	5
168	Risk Indices in Deceased-donor Organ Allocation for Transplantation: Review From an Australian Perspective. Transplantation, 2019, 103, 875-889.	0.5	5
169	Effect of centreâ€•and patientâ€•related factors on uptake of haemodiafiltration in Australia and New Zealand: A cohort study using ANZDATA. Nephrology, 2020, 25, 63-72.	0.7	5
170	Vitamin D therapy in chronic kidney disease: back to the future?. Clinical Nephrology, 2015, 84 (2015), 65-74.	0.4	5
171	Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. Internal Medicine Journal, 2011, 41, 825-832.	0.5	4
172	Association between initial and pretransplant dialysis modality and graft and patient outcomes in live- and deceased-donor renal transplant recipients. Transplant International, 2012, 25, 1032-1040.	0.8	4
173	Arteriovenous access practices in Australian and New Zealand dialysis units. Journal of Vascular Access, 2019, 20, 740-745.	0.5	4
174	Volume management in haemodialysis patients. Current Opinion in Nephrology and Hypertension, 2020, 29, 663-670.	1.0	4
175	Predicting vascular access failure: A collective review. Nephrology, 2002, 7, 170-176.	0.7	3
176	A Decade After the KDOQI CKD Guidelines: A Perspective From Australia. American Journal of Kidney Diseases, 2012, 60, 725-726.	2.1	3
177	Willingness to Participate in a Randomized Trial Comparing Catheters to Fistulas for Vascular Access in Incident Hemodialysis Patients: An International Survey of Nephrologists. Canadian Journal of Kidney Health and Disease, 2016, 3, 125.	0.6	3
178	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology, 2017, 22, 823-824.	0.7	3
179	Comparing dialysis centre mortality outcomes across Australia and New Zealand: identifying unusually performing centres 2008â€“2013. BMC Health Services Research, 2018, 18, 1007.	0.9	3
180	Câ€•reactive protein levels in acute respiratory exacerbations of cystic fibrosis. Internal Medicine Journal, 2018, 48, 1392-1395.	0.5	3

#	Article	IF	Citations
181	Biochemical comparison of 8 h haemodialysis and 4 h haemodiafiltration, and two dialysis membranes, in a randomized crossâ€over trial. Nephrology, 2019, 24, 542-549.	0.7	3
182	The impact of antineutrophil cytoplasmic antibodyâ€associated vasculitis on employment and work disability in an Australian population. International Journal of Rheumatic Diseases, 2021, 24, 904-911.	0.9	3
183	Reproducibility of Urinary Albumin Assays by Immunonephelometry After Long-term Storage at â^'70Â°C. American Journal of Kidney Diseases, 2011, 58, 685-687.	2.1	2
184	Efficacy of patient questionnaire in predicting renal dysfunction in outpatients older than 60â€ƒyears of age prior to contrast-enhanced computed tomography. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 168-172.	0.9	2
185	Vascular Access, Mortality, and Home Hemodialysis: Back to the Future. American Journal of Kidney Diseases, 2016, 67, 176-178.	2.1	2
186	FP555EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON NEED FOR ARTERIOVENOUS FISTULA INTERVENTIONS AND CENTRAL VENOUS CATHETERS IN PATIENTS REQUIRING HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2018, 33, i227-i227.	0.4	2
187	Home and facility haemodialysis patients: a comparison of outcomes in a matched cohort. Nephrology Dialysis Transplantation, 2021, 36, 1070-1077.	0.4	2
188	Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry. Kidney360, 2021, 2, 674-683.	0.9	2
189	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	0.8	2
190	CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort. Kidney360, 2022, 3, 435-445.	0.9	2
191	Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial. American Journal of Kidney Diseases, 2022, 80, 810-813.	2.1	2
192	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. Journal of Vascular Access, 2024, 25, 193-202.	0.5	2
193	Missing Data and Multiple Imputation When Predicting Mortality in Incident Dialysis Patients. American Journal of Kidney Diseases, 2011, 58, 679.	2.1	1
194	Population Prevalance of Proteinuria and Diagnostic Accuracy of Urine Dipsticks. American Journal of Kidney Diseases, 2011, 58, 1039.	2.1	1
195	How Can the Complications of Central Vein Catheters Be Reduced?. Seminars in Dialysis, 2016, 29, 197-198.	0.7	1
196	Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1694-1695.	2.2	1
197	Practice patterns and predictors of outpatient care following acute kidney injury in an Australian healthcare setting. Internal Medicine Journal, 2022, 52, 79-88.	0.5	1
198	Risk indices predicting graft use, graft and patient survival in solid pancreas transplantation: a systematic review. BMC Gastroenterology, 2021, 21, 80.	0.8	1

#	Article	IF	Citations
199	Results from an International Survey of Donor and Recipient Eligibility for Solid Organ Pancreas Transplantation. Annals of Transplantation, 2021, 26, e930787.	0.5	1
200	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. Nephrology Dialysis Transplantation, 2022, 37, 1472-1481.	0.4	1
201	Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective. Kidney360, 2020, 1, 829-833.	0.9	1
202	Taking a broader view of the health care needs of people with chronic kidney disease. Medical Journal of Australia, 2022, 216, 137-138.	0.8	1
203	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
204	BK Virus Associated Nephropathy, a Cause of Early Renal Allograft Dysfunction: A Single Centre Study. Kathmandu University Medical Journal, 2017, 13, 140-145.	0.1	0
205	Long-Term Graft and Patient Outcomes Following Kidney Transplantation in End-Stage Kidney Disease Secondary to Hyperoxaluria. Transplantation Proceedings, 2021, 53, 839-847.	0.3	0
206	Variability and trends over time and across centres in haemodialysis weekly duration in Australia and New Zealand. Nephrology, 2021, 26, 153-163.	0.7	0
207	Donor Predictors of Donor Pancreas Retrieval and Subsequent Solid Pancreas Transplantation in Australia and New Zealand from 2007 to 2016. Transplantation Proceedings, 2021, 53, 2358-2368.	0.3	0
208	Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A preâ€specified crossâ€sectional study of the FAVOURED trial participants. Journal of Human Nutrition and Dietetics, 2022, 35, 1178-1191.	1.3	0
209	Vascular Access for Hemodialysis. , 0, , 460-467.		0